{{scheme.chgp}}%
{{scheme.chgp}}%
No Matches Found
{{scheme.chgp}}%
No Matches Found
No Matches Found
Is Masimo Corp. technically bullish or bearish?
As of October 10, 2025, Masimo Corp. is in a bearish trend with weak strength indicators, underperforming the S&P 500 with a year-to-date return of -12.50% and a five-year decline of -40.34%.
Masimo Corp. Experiences Revision in Stock Evaluation Amid Mixed Market Signals
Masimo Corp., a small-cap company in the Pharmaceuticals & Biotechnology sector, has seen a slight stock price increase to $148.13. Over the past year, it has returned 6.70%, significantly underperforming the S&P 500's 17.82%. Technical indicators show mixed signals, reflecting potential volatility and challenges ahead.
Is Masimo Corp. technically bullish or bearish?
As of October 3, 2025, Masimo Corp. shows a mildly bearish technical trend, with underperformance compared to the S&P 500, reflecting a year-to-date return of -10.39% versus 14.18% for the index.
Is Masimo Corp. technically bullish or bearish?
As of October 3, 2025, Masimo Corp. shows a mildly bearish technical trend with short-term strength, having outperformed the S&P 500 recently but underperformed year-to-date.
Is Masimo Corp. technically bullish or bearish?
As of October 3, 2025, Masimo Corp. shows a mildly bearish technical trend, with recent performance outperforming the S&P 500 over the past week and month but underperforming year-to-date.
Is Masimo Corp. technically bullish or bearish?
As of September 9, 2025, Masimo Corp. has shifted to a bearish trend with weak strength indicators, underperforming the S&P 500 year-to-date by -13.49% compared to its 12.22% gain.
Is Masimo Corp. overvalued or undervalued?
As of February 25, 2025, Masimo Corp. is considered overvalued and risky due to its high P/E ratio of 409 and negative YTD return of -13.49%, significantly underperforming compared to industry peers and the S&P 500.
Is Masimo Corp. overvalued or undervalued?
As of February 25, 2025, Masimo Corp. is considered overvalued with a valuation grade of risky, highlighted by a P/E ratio of 409 and low returns on capital, making it an unsound investment despite recent stock performance.
Is Masimo Corp. technically bullish or bearish?
As of June 20, 2025, Masimo Corp. shows a bullish technical trend supported by positive MACD and Bollinger Bands, though caution is advised due to a mildly bearish view from Dow Theory.
Who are in the management team of Masimo Corp.?
As of March 2022, the management team of Masimo Corp. is led by Mr. Joseph Kiani, Chairman and CEO, alongside Independent Directors Dr. Steven Barker, Mr. H. Michael Cohen, Mr. Sanford Fitch, Sen. (Retd.) Thomas Harkin, and Mr. Adam Mikkelson.
What does Masimo Corp. do?
Masimo Corporation is a mid-cap medical technology company specializing in non-invasive patient monitoring technologies, with net sales of $372 million and a market cap of approximately $11.27 billion as of March 2025. Key financial metrics include a P/E ratio of 409.00 and a return on equity of 3.14%.
How big is Masimo Corp.?
As of Jun 18, Masimo Corp. has a market capitalization of $11.27 billion, with recent net sales of $1.97 billion and a net profit of -$276.6 million. Shareholder's funds are $1.05 billion, and total assets amount to $2.63 billion.
{{list.post_title}}
{{list.post_excerpt}}
{{list.post_title}}
{{list.post_excerpt}}
